The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Stopped strategy terminates development, the decision is not due to any safety-related issues

Conditions

• Non-squamous Non-small-cell Lung Cancer

Interventions

• DRUG: Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed
• DRUG: Sintilimab+Carboplatin or Cisplatin+Pemetrexed
• DRUG: Tusamitamab ravtansine+Sintilimab

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.